Background and Case Definition
A European medical-device manufacturer sells a mature diagnostic platform in several international markets and is assessing China. Hospitals value the technology, but the company faces national product registration, service coverage, procurement pressure, local clinical expectations and questions about whether to import, assemble or manufacture locally.
The case is a decision model rather than a claim about a fictional German company achieving invented growth or regulatory results. The objective is to show how localization can be phased without confusing manufacturing investment with product approval or assuming that local production automatically creates procurement access.
Challenge: Starting Position
The product consists of capital equipment, software, disposable components and maintenance services. China customers require installation, training, calibration and timely repair. Imported sales can validate clinical and commercial demand, but service delays and landed cost may weaken the offer. Local manufacturing could improve supply and tender responsiveness while creating quality, supplier and technology-transfer risk.
Management separates four decisions: product registration, commercial access, service localization and manufacturing localization. They interact, but none is allowed to hide the others. A China company does not replace NMPA registration, and an NMPA certificate does not guarantee hospital purchases or reimbursement.
Approach, Phase 1: Regulatory and Market Feasibility
The team confirms intended use, device classification, product configuration and the applicable registration route. It reviews foreign marketing evidence, standards, testing, clinical evaluation, software, cybersecurity, labeling, quality systems and the responsibilities of the overseas registrant and China agent. Product versions are controlled so the registered configuration matches the commercial offer.
In parallel, the commercial team interviews hospitals, clinicians, distributors and service providers. It tests clinical use cases, installed-base requirements, procurement route, budget ownership, competitor pricing and service expectations. Market size is not accepted as proof of an addressable segment; the team needs institutions that can use and fund the product.
Phase 2: Import and Service Localization
If regulatory and customer evidence supports entry, the company establishes a compliant import and service model. It defines the registration holder or agent relationship, importer, distributor responsibilities, complaint handling, adverse-event reporting, recalls, spare parts and technical training. Contracts preserve manufacturer access to safety and performance information.
A local technical team can improve uptime before production is localized. The company creates controlled service manuals, parts inventories, calibration processes and escalation to global engineering. Access to software, logs and patient-related information is role-based and reviewed under Chinese data rules.
Phase 3: Selective Assembly or Packaging
Local assembly should solve a documented cost, lead-time, tender or supply problem. The team identifies which operations can move without undermining quality or requiring uncontrolled transfer of core know-how. It assesses premises, environmental requirements, manufacturing licenses, supplier qualification, process validation and changes to the registered product.
The regulatory impact of localization is reviewed before equipment is ordered. A change in manufacturer, site, process, materials or software can affect the product filing and evidence. The company does not assume that imported and locally produced versions can be substituted without formal change control.
Phase 4: Full Manufacturing Decision
Full production is considered after demand, tender access, service performance and the supplier base are proven. The investment model includes quality staff, validation, clean or controlled environments where required, utilities, environmental controls, testing, inventory and working capital. It also includes the cost of maintaining consistency between global and China product versions.
A wholly owned operation offers control, while contract manufacturing or a joint venture may reduce initial investment. Each alternative is assessed for regulatory responsibility, quality oversight, intellectual property, access to records, audit rights, business continuity and termination. Price alone is not sufficient for a regulated product.
Procurement and Commercial Reality
Hospital procurement can involve national and local policy, tender requirements, volume-based procurement for selected products, clinical evaluation and budget constraints. A local manufacturing address should not be marketed internally as a guaranteed procurement preference. The team verifies each tender and policy from the responsible authority.
The company builds channel economics from the final customer price backward. Distributor margin, service, tax, logistics, demonstration equipment, payment periods and tender discounts are included. Exclusivity requires measurable performance and does not prevent the manufacturer from receiving safety and complaint data.
Quality and Post-Market Control
China operations are integrated into the global quality system with clearly assigned local responsibilities. Complaint intake, adverse-event evaluation, field safety action, recall, supplier changes, software updates and corrective action need accessible records and defined escalation. Commercial partners are trained to identify reportable events rather than treating complaints only as sales issues.
Localization increases the number of change points. The company maintains a product and process configuration record showing what is approved, produced and installed. Quality release cannot be subordinated to a monthly shipment target.
Data and Software Governance
Diagnostic devices can generate personal information, health data, logs and algorithm inputs. The company maps where data are collected, hosted, accessed and transferred. Clinical care, device support, vigilance and research use are treated as different purposes. Overseas access follows a lawful route and the minimum-data principle.
Software updates are assessed for regulatory significance, cybersecurity, validation and customer notification. A local development team receives only the code and data needed for its approved role. Localized innovation is valuable when ownership of improvements, documentation and global reuse have been agreed in advance.
Lessons and Investment Gates
- Confirm product classification and registration feasibility.
- Validate clinical demand, procurement route and service requirements.
- Build compliant import, distribution and post-market controls.
- Localize service before manufacturing where service is the immediate gap.
- Approve assembly only with regulatory change analysis and quality controls.
- Approve full manufacturing after demand and supply assumptions are evidenced.
Result: Phased Localization
The company adopts phased localization. Registration and customer validation come first, service capability second, and production only when it solves a measured constraint. This sequence keeps capital decisions connected to regulatory evidence and market demand without promising an arbitrary launch date or financial result.
Official Sources
- National Health Commission: Regulations for the Supervision and Administration of Medical Devices
- National Medical Products Administration: Measures for Medical Device Registration and Filing
- National Development and Reform Commission: current foreign-investment negative list
- Cyberspace Administration of China: cross-border data flow provisions
